[{"run_id":"20261014T203208-0851c9a1","observed_at":"2026-10-14 17:50:09.728220+00:00","course_uid":"course_3fccebda183122da4a95adb6","course_id":"PHMSCI 770","catalog_version_id":"0cf9d39503f57a361961824645422b3c707ec8e9ae93ca29aa86cd5d41fcc6bd","record_version_id":"3ddf615594aad5b59aa7956995d2511a271a5afcf813978a8b45fc10086d6f3e","job_id":"enrich-49752a259f17fab0f49665b3","output_id":"474c0fc18b92938c88cdfd25b8c7d1a3e7907d5d9a6c5a77041940051cd7e99d","section":"requirements","status":"valid","value_json":"{\"nodes\":[{\"children\":[],\"condition\":\"Declared in MS Pharmaceutical Sciences\",\"course\":null,\"evidence\":\"Declared in MS Pharmaceutical Sciences\",\"id\":\"req-1\",\"kind\":\"condition\"}],\"notes\":[],\"root\":\"req-1\",\"status\":\"parsed\"}","candidate_json":null,"error":null,"model":"Qwen/Qwen3.8-27B","model_revision":"1d4bf0f2ff6012fd82039f2fa52739d0dd7c60c0","selected_for_release":true},{"run_id":"20261014T203208-0851c9a1","observed_at":"2026-10-14 17:50:09.728220+00:00","course_uid":"course_3fccebda183122da4a95adb6","course_id":"PHMSCI 770","catalog_version_id":"0cf9d39503f57a361961824645422b3c707ec8e9ae93ca29aa86cd5d41fcc6bd","record_version_id":"3ddf615594aad5b59aa7956995d2511a271a5afcf813978a8b45fc10086d6f3e","job_id":"enrich-49752a259f17fab0f49665b3","output_id":"474c0fc18b92938c88cdfd25b8c7d1a3e7907d5d9a6c5a77041940051cd7e99d","section":"search_profile","status":"valid","value_json":"{\"activity_tags\":[{\"evidence\":[{\"course_id\":\"PHMSCI 770\",\"field\":\"description\",\"quote\":\"Develops skills in primary literature analysis to enable conceptual integration of information across chemical, molecular, cellular, systems, and societal levels.\",\"source_url\":\"https://guide.wisc.edu/courses/phm_sci/\"}],\"label\":\"data-analysis\"}],\"assumed_background\":[],\"search_phrases\":[\"CNS drug design\",\"cholinergic pharmaceuticals\",\"glutamatergic drugs\",\"central nervous system pharmacology\",\"molecular targets CNS\",\"drug access to CNS\",\"neurotransmitter physiology\",\"psychiatric condition treatment\"],\"skills_taught\":[{\"evidence\":[{\"course_id\":\"PHMSCI 770\",\"field\":\"description\",\"quote\":\"Develops skills in primary literature analysis to enable conceptual integration of information across chemical, molecular, cellular, systems, and societal levels.\",\"source_url\":\"https://guide.wisc.edu/courses/phm_sci/\"}],\"text\":\"Primary literature analysis and conceptual integration across multiple biological levels\"},{\"evidence\":[{\"course_id\":\"PHMSCI 770\",\"field\":\"official_learning_outcomes\",\"outcome_index\":4,\"quote\":\"Match psychiatric conditions and target symptoms of these conditions with appropriate cholinergic and glutamatergic pharmaceuticals.\",\"source_url\":\"https://guide.wisc.edu/courses/phm_sci/\"}],\"text\":\"Matching psychiatric conditions with appropriate cholinergic and glutamatergic pharmaceuticals\"},{\"evidence\":[{\"course_id\":\"PHMSCI 770\",\"field\":\"official_learning_outcomes\",\"outcome_index\":1,\"quote\":\"List physicochemical properties of drugs, anatomical structures and molecular machinery that influence drug access to and efflux from the CNS.\",\"source_url\":\"https://guide.wisc.edu/courses/phm_sci/\"}],\"text\":\"Identifying physicochemical properties influencing CNS drug access and efflux\"}],\"summary\":{\"evidence\":[{\"course_id\":\"PHMSCI 770\",\"field\":\"title\",\"quote\":\"CNS DRUG DESIGNS, ACTIONS, AND APPLICATIONS I\",\"source_url\":\"https://guide.wisc.edu/courses/phm_sci/\"},{\"course_id\":\"PHMSCI 770\",\"field\":\"description\",\"quote\":\"Explores how chemical properties influence molecular targets in the central nervous system (CNS), how altered signaling drives physiological changes, and how cholinergic and glutamatergic pharmaceuticals improve patient outcomes.\",\"source_url\":\"https://guide.wisc.edu/courses/phm_sci/\"}],\"text\":\"Explores how chemical properties influence CNS molecular targets and how cholinergic and glutamatergic pharmaceuticals improve patient outcomes through altered signaling.\"},\"topics\":[{\"evidence\":[{\"course_id\":\"PHMSCI 770\",\"field\":\"official_learning_outcomes\",\"outcome_index\":2,\"quote\":\"Describe the major neurotransmitters of the central nervous system, including their physiologic role, distribution, synthesis, storage, and release.\",\"source_url\":\"https://guide.wisc.edu/courses/phm_sci/\"}],\"text\":\"Major CNS neurotransmitters: role, distribution, synthesis, storage, and release\"},{\"evidence\":[{\"course_id\":\"PHMSCI 770\",\"field\":\"official_learning_outcomes\",\"outcome_index\":3,\"quote\":\"Recall the principal mechanisms by which receptors affect cellular signaling in the Central Nervous System.\",\"source_url\":\"https://guide.wisc.edu/courses/phm_sci/\"}],\"text\":\"Receptor mechanisms affecting cellular signaling in the CNS\"},{\"evidence\":[{\"course_id\":\"PHMSCI 770\",\"field\":\"official_learning_outcomes\",\"outcome_index\":5,\"quote\":\"Describe common / serious adverse effects of cholinergic and glutamatergic pharmaceuticals and methods for preventing or minimizing their occurrence.\",\"source_url\":\"https://guide.wisc.edu/courses/phm_sci/\"}],\"text\":\"Adverse effects of cholinergic and glutamatergic pharmaceuticals and prevention methods\"},{\"evidence\":[{\"course_id\":\"PHMSCI 770\",\"field\":\"official_learning_outcomes\",\"outcome_index\":0,\"quote\":\"Identify CNS active drug classes and origins of cholinergic and glutamatergic drugs based in part on structural aspects of the molecule.\",\"source_url\":\"https://guide.wisc.edu/courses/phm_sci/\"}],\"text\":\"Structural aspects of cholinergic and glutamatergic drugs and CNS active classes\"}]}","candidate_json":null,"error":null,"model":"Qwen/Qwen3.8-27B","model_revision":"1d4bf0f2ff6012fd82039f2fa52739d0dd7c60c0","selected_for_release":true},{"run_id":"20261014T203208-0851c9a1","observed_at":"2026-10-14 17:50:09.728220+00:00","course_uid":"course_3fccebda183122da4a95adb6","course_id":"PHMSCI 770","catalog_version_id":"0cf9d39503f57a361961824645422b3c707ec8e9ae93ca29aa86cd5d41fcc6bd","record_version_id":"3ddf615594aad5b59aa7956995d2511a271a5afcf813978a8b45fc10086d6f3e","job_id":"enrich-49752a259f17fab0f49665b3","output_id":"474c0fc18b92938c88cdfd25b8c7d1a3e7907d5d9a6c5a77041940051cd7e99d","section":"student_experience","status":"insufficient_evidence","value_json":"{\"status\":\"insufficient_evidence\",\"themes\":[]}","candidate_json":null,"error":null,"model":"Qwen/Qwen3.8-27B","model_revision":"1d4bf0f2ff6012fd82039f2fa52739d0dd7c60c0","selected_for_release":true},{"run_id":"20261014T203208-0851c9a1","observed_at":"2026-10-14 17:50:09.728220+00:00","course_uid":"course_3fccebda183122da4a95adb6","course_id":"PHMSCI 770","catalog_version_id":"0cf9d39503f57a361961824645422b3c707ec8e9ae93ca29aa86cd5d41fcc6bd","record_version_id":"3ddf615594aad5b59aa7956995d2511a271a5afcf813978a8b45fc10086d6f3e","job_id":"enrich-49752a259f17fab0f49665b3","output_id":"474c0fc18b92938c88cdfd25b8c7d1a3e7907d5d9a6c5a77041940051cd7e99d","section":"student_summary","status":"valid","value_json":"{\"context_hash\":\"a24a3442b298a7159e9f17fc3e8b6fb4fb47f023138e43fe20862cc0f8d73dff\",\"course_id\":\"PHMSCI 770\",\"current_instructors\":[],\"difficulty_workload\":[],\"errors\":[],\"historical_context\":[],\"message\":\"No course-specific reviews available\",\"offered\":false,\"profile_hash\":\"3f5110430805ccdd533c0c072df62d68a8a5f5441c4530bbdb15d419a199a09c\",\"quick_take\":[{\"citations\":[{\"course_id\":\"PHMSCI 770\",\"run_id\":\"20261014T203208-0851c9a1\",\"source_record\":{\"entity_id\":\"ee8e37bd-e595-3df5-a266-87f2b3460a8a\",\"file\":\"tables/observations.parquet\",\"kind\":\"grades\",\"source\":\"madgrades\"},\"table\":\"grades_latest\",\"term_id\":\"1074\",\"type\":\"grade\"}],\"text\":\"Recent recorded grades — Spring 2007: 3.77 GPA, 92.3% A/AB (n=13 letter grades).\"}],\"student_experience\":[],\"task_hash\":\"9dea82ef7f2113a5605c1c6030c4f9b19967eb742cc93a78268fb92357d29f5c\",\"teaching_history\":[],\"term_id\":\"1274\",\"term_name\":\"2027 Sprng\",\"version\":3}","candidate_json":null,"error":null,"model":"Qwen/Qwen3.8-27B","model_revision":"1d4bf0f2ff6012fd82039f2fa52739d0dd7c60c0","selected_for_release":true},{"run_id":"20260906T231458-5fdd2fff","observed_at":"2026-09-06 23:14:58.172943+00:00","course_uid":"course_3fccebda183122da4a95adb6","course_id":"PHMSCI 770","catalog_version_id":"f6477f279dae5c75278010d122a5ffa7397ded5a5db8c1ec0a762d14306f6467","record_version_id":"3fe82b78da6106da037370637cb182711f649ef50c59fe8ba86c8554e0a230bf","job_id":"enrich-5291a20b802b9bbbe22b24cb","output_id":"84ab0836e30712e66a625cb48dcba1b03c7230972fb23a02ff5eefa7aadadc40","section":"requirements","status":"valid","value_json":"{\"nodes\":[{\"children\":[],\"condition\":\"Declared in MS Pharmaceutical Sciences\",\"course\":null,\"evidence\":\"Declared in MS Pharmaceutical Sciences\",\"id\":\"n0\",\"kind\":\"condition\"}],\"notes\":[],\"root\":\"n0\",\"status\":\"parsed\"}","candidate_json":null,"error":null,"model":"nvidia/Qwen3.6-35B-A3B-NVFP4","model_revision":"1355db6a052410cfd62085d94b58866fd0f2c3c5","selected_for_release":false},{"run_id":"20260906T231458-5fdd2fff","observed_at":"2026-09-06 23:14:58.172943+00:00","course_uid":"course_3fccebda183122da4a95adb6","course_id":"PHMSCI 770","catalog_version_id":"f6477f279dae5c75278010d122a5ffa7397ded5a5db8c1ec0a762d14306f6467","record_version_id":"3fe82b78da6106da037370637cb182711f649ef50c59fe8ba86c8554e0a230bf","job_id":"enrich-5291a20b802b9bbbe22b24cb","output_id":"84ab0836e30712e66a625cb48dcba1b03c7230972fb23a02ff5eefa7aadadc40","section":"search_profile","status":"valid","value_json":"{\"assumed_background\":[{\"evidence\":[{\"course_id\":\"PHMSCI 770\",\"field\":\"description\",\"quote\":\"Explores how chemical properties influence molecular targets in the central nervous system (CNS), how altered signaling drives physiological changes, and how cholinergic and glutamatergic pharmaceuticals improve patient outcomes.\"}],\"text\":\"Foundational knowledge in chemistry, molecular biology, and pharmacology related to the central nervous system.\"}],\"search_phrases\":[\"CNS drug design\",\"molecular targets central nervous system\",\"cholinergic glutamatergic pharmaceuticals\",\"primary literature analysis skills\",\"pharmaceutical sciences graduate course\"],\"skills_taught\":[{\"evidence\":[{\"course_id\":\"PHMSCI 770\",\"field\":\"description\",\"quote\":\"Develops skills in primary literature analysis to enable conceptual integration of information across chemical, molecular, cellular, systems, and societal levels.\"}],\"text\":\"Primary literature analysis and conceptual integration across multiple biological and chemical levels.\"}],\"summary\":{\"evidence\":[{\"course_id\":\"PHMSCI 770\",\"field\":\"title\",\"quote\":\"CNS DRUG DESIGNS, ACTIONS, AND APPLICATIONS I\"},{\"course_id\":\"PHMSCI 770\",\"field\":\"description\",\"quote\":\"Explores how chemical properties influence molecular targets in the central nervous system (CNS)\"}],\"text\":\"PHMSCI 770 explores chemical influences on CNS molecular targets and develops primary literature analysis skills.\"},\"topics\":[{\"evidence\":[{\"course_id\":\"PHMSCI 770\",\"field\":\"description\",\"quote\":\"chemical properties influence molecular targets in the central nervous system (CNS)\"}],\"text\":\"Chemical properties and molecular targets in the CNS\"},{\"evidence\":[{\"course_id\":\"PHMSCI 770\",\"field\":\"description\",\"quote\":\"altered signaling drives physiological changes\"}],\"text\":\"Altered signaling and physiological changes\"},{\"evidence\":[{\"course_id\":\"PHMSCI 770\",\"field\":\"description\",\"quote\":\"cholinergic and glutamatergic pharmaceuticals improve patient outcomes\"}],\"text\":\"Cholinergic and glutamatergic pharmaceuticals\"},{\"evidence\":[{\"course_id\":\"PHMSCI 770\",\"field\":\"description\",\"quote\":\"conceptual integration of information across chemical, molecular, cellular, systems, and societal levels\"}],\"text\":\"Conceptual integration across chemical, molecular, cellular, systems, and societal levels\"}]}","candidate_json":null,"error":null,"model":"nvidia/Qwen3.6-35B-A3B-NVFP4","model_revision":"1355db6a052410cfd62085d94b58866fd0f2c3c5","selected_for_release":false},{"run_id":"20260906T231458-5fdd2fff","observed_at":"2026-09-06 23:14:58.172943+00:00","course_uid":"course_3fccebda183122da4a95adb6","course_id":"PHMSCI 770","catalog_version_id":"f6477f279dae5c75278010d122a5ffa7397ded5a5db8c1ec0a762d14306f6467","record_version_id":"3fe82b78da6106da037370637cb182711f649ef50c59fe8ba86c8554e0a230bf","job_id":"enrich-5291a20b802b9bbbe22b24cb","output_id":"84ab0836e30712e66a625cb48dcba1b03c7230972fb23a02ff5eefa7aadadc40","section":"student_experience","status":"insufficient_evidence","value_json":"{\"status\":\"insufficient_evidence\",\"themes\":[]}","candidate_json":null,"error":null,"model":"nvidia/Qwen3.6-35B-A3B-NVFP4","model_revision":"1355db6a052410cfd62085d94b58866fd0f2c3c5","selected_for_release":false},{"run_id":"20260907T155543-ce3781c4","observed_at":"2026-09-07 15:55:43.033547+00:00","course_uid":"course_3fccebda183122da4a95adb6","course_id":"PHMSCI 770","catalog_version_id":"f6477f279dae5c75278010d122a5ffa7397ded5a5db8c1ec0a762d14306f6467","record_version_id":"3fe82b78da6106da037370637cb182711f649ef50c59fe8ba86c8554e0a230bf","job_id":"enrich-5590a4969e0a630fe46a86e8","output_id":"2eff4828e98fe29bcf7405044a6e700c9b3b7c355fd860d5a20e65e5db71a9f0","section":"requirements","status":"valid","value_json":"{\"nodes\":[{\"children\":[],\"condition\":\"Declared in MS Pharmaceutical Sciences\",\"course\":null,\"evidence\":\"Declared in MS Pharmaceutical Sciences\",\"id\":\"n0\",\"kind\":\"condition\"}],\"notes\":[],\"root\":\"n0\",\"status\":\"parsed\"}","candidate_json":null,"error":null,"model":"nvidia/Qwen3.6-35B-A3B-NVFP4","model_revision":"1355db6a052410cfd62085d94b58866fd0f2c3c5","selected_for_release":false},{"run_id":"20260907T155543-ce3781c4","observed_at":"2026-09-07 15:55:43.033547+00:00","course_uid":"course_3fccebda183122da4a95adb6","course_id":"PHMSCI 770","catalog_version_id":"f6477f279dae5c75278010d122a5ffa7397ded5a5db8c1ec0a762d14306f6467","record_version_id":"3fe82b78da6106da037370637cb182711f649ef50c59fe8ba86c8554e0a230bf","job_id":"enrich-5590a4969e0a630fe46a86e8","output_id":"2eff4828e98fe29bcf7405044a6e700c9b3b7c355fd860d5a20e65e5db71a9f0","section":"search_profile","status":"valid","value_json":"{\"assumed_background\":[{\"evidence\":[{\"course_id\":\"PHMSCI 770\",\"field\":\"description\",\"quote\":\"Explores how chemical properties influence molecular targets in the central nervous system (CNS), how altered signaling drives physiological changes, and how cholinergic and glutamatergic pharmaceuticals improve patient outcomes.\"}],\"text\":\"Foundational knowledge in chemistry, molecular biology, and pharmacology related to the central nervous system.\"}],\"search_phrases\":[\"CNS drug design\",\"molecular targets central nervous system\",\"cholinergic glutamatergic pharmaceuticals\",\"primary literature analysis skills\",\"pharmaceutical sciences graduate course\"],\"skills_taught\":[{\"evidence\":[{\"course_id\":\"PHMSCI 770\",\"field\":\"description\",\"quote\":\"Develops skills in primary literature analysis to enable conceptual integration of information across chemical, molecular, cellular, systems, and societal levels.\"}],\"text\":\"Primary literature analysis and conceptual integration across multiple biological and chemical levels.\"}],\"summary\":{\"evidence\":[{\"course_id\":\"PHMSCI 770\",\"field\":\"title\",\"quote\":\"CNS DRUG DESIGNS, ACTIONS, AND APPLICATIONS I\"},{\"course_id\":\"PHMSCI 770\",\"field\":\"description\",\"quote\":\"Explores how chemical properties influence molecular targets in the central nervous system (CNS)\"}],\"text\":\"PHMSCI 770 explores chemical influences on CNS molecular targets and develops primary literature analysis skills.\"},\"topics\":[{\"evidence\":[{\"course_id\":\"PHMSCI 770\",\"field\":\"description\",\"quote\":\"chemical properties influence molecular targets in the central nervous system (CNS)\"}],\"text\":\"Chemical properties and molecular targets in the CNS\"},{\"evidence\":[{\"course_id\":\"PHMSCI 770\",\"field\":\"description\",\"quote\":\"altered signaling drives physiological changes\"}],\"text\":\"Altered signaling and physiological changes\"},{\"evidence\":[{\"course_id\":\"PHMSCI 770\",\"field\":\"description\",\"quote\":\"cholinergic and glutamatergic pharmaceuticals improve patient outcomes\"}],\"text\":\"Cholinergic and glutamatergic pharmaceuticals\"},{\"evidence\":[{\"course_id\":\"PHMSCI 770\",\"field\":\"description\",\"quote\":\"conceptual integration of information across chemical, molecular, cellular, systems, and societal levels\"}],\"text\":\"Conceptual integration across chemical, molecular, cellular, systems, and societal levels\"}]}","candidate_json":null,"error":null,"model":"nvidia/Qwen3.6-35B-A3B-NVFP4","model_revision":"1355db6a052410cfd62085d94b58866fd0f2c3c5","selected_for_release":false},{"run_id":"20260907T155543-ce3781c4","observed_at":"2026-09-07 15:55:43.033547+00:00","course_uid":"course_3fccebda183122da4a95adb6","course_id":"PHMSCI 770","catalog_version_id":"f6477f279dae5c75278010d122a5ffa7397ded5a5db8c1ec0a762d14306f6467","record_version_id":"3fe82b78da6106da037370637cb182711f649ef50c59fe8ba86c8554e0a230bf","job_id":"enrich-5590a4969e0a630fe46a86e8","output_id":"2eff4828e98fe29bcf7405044a6e700c9b3b7c355fd860d5a20e65e5db71a9f0","section":"student_experience","status":"insufficient_evidence","value_json":"{\"status\":\"insufficient_evidence\",\"themes\":[]}","candidate_json":null,"error":null,"model":"nvidia/Qwen3.6-35B-A3B-NVFP4","model_revision":"1355db6a052410cfd62085d94b58866fd0f2c3c5","selected_for_release":false},{"run_id":"20261014T203208-0851c9a1","observed_at":"2026-10-14 17:50:09.728220+00:00","course_uid":"course_3fccebda183122da4a95adb6","course_id":"PHMSCI 770","catalog_version_id":"0cf9d39503f57a361961824645422b3c707ec8e9ae93ca29aa86cd5d41fcc6bd","record_version_id":"3ddf615594aad5b59aa7956995d2511a271a5afcf813978a8b45fc10086d6f3e","job_id":"enrich-6556a505c10f448d98d02466","output_id":"141adddc0e7045dcc2de75d2697107d842d2156cdcd111388012bfe7eee3b41c","section":"requirements","status":"valid","value_json":"{\"nodes\":[{\"children\":[],\"condition\":\"Declared in MS Pharmaceutical Sciences\",\"course\":null,\"evidence\":\"Declared in MS Pharmaceutical Sciences\",\"id\":\"req-1\",\"kind\":\"condition\"}],\"notes\":[],\"root\":\"req-1\",\"status\":\"parsed\"}","candidate_json":null,"error":null,"model":"Qwen/Qwen3.8-27B","model_revision":"1d4bf0f2ff6012fd82039f2fa52739d0dd7c60c0","selected_for_release":false},{"run_id":"20261014T203208-0851c9a1","observed_at":"2026-10-14 17:50:09.728220+00:00","course_uid":"course_3fccebda183122da4a95adb6","course_id":"PHMSCI 770","catalog_version_id":"0cf9d39503f57a361961824645422b3c707ec8e9ae93ca29aa86cd5d41fcc6bd","record_version_id":"3ddf615594aad5b59aa7956995d2511a271a5afcf813978a8b45fc10086d6f3e","job_id":"enrich-6556a505c10f448d98d02466","output_id":"141adddc0e7045dcc2de75d2697107d842d2156cdcd111388012bfe7eee3b41c","section":"search_profile","status":"valid","value_json":"{\"activity_tags\":[{\"evidence\":[{\"course_id\":\"PHMSCI 770\",\"field\":\"description\",\"quote\":\"Develops skills in primary literature analysis to enable conceptual integration of information across chemical, molecular, cellular, systems, and societal levels.\",\"source_url\":\"https://guide.wisc.edu/courses/phm_sci/\"}],\"label\":\"data-analysis\"}],\"assumed_background\":[],\"search_phrases\":[\"CNS drug design\",\"cholinergic pharmaceuticals\",\"glutamatergic drugs\",\"central nervous system pharmacology\",\"molecular targets CNS\",\"drug access to CNS\",\"neurotransmitter physiology\",\"psychiatric condition treatment\"],\"skills_taught\":[{\"evidence\":[{\"course_id\":\"PHMSCI 770\",\"field\":\"description\",\"quote\":\"Develops skills in primary literature analysis to enable conceptual integration of information across chemical, molecular, cellular, systems, and societal levels.\",\"source_url\":\"https://guide.wisc.edu/courses/phm_sci/\"}],\"text\":\"Primary literature analysis and conceptual integration across multiple biological levels\"},{\"evidence\":[{\"course_id\":\"PHMSCI 770\",\"field\":\"official_learning_outcomes\",\"outcome_index\":4,\"quote\":\"Match psychiatric conditions and target symptoms of these conditions with appropriate cholinergic and glutamatergic pharmaceuticals.\",\"source_url\":\"https://guide.wisc.edu/courses/phm_sci/\"}],\"text\":\"Matching psychiatric conditions with appropriate cholinergic and glutamatergic pharmaceuticals\"},{\"evidence\":[{\"course_id\":\"PHMSCI 770\",\"field\":\"official_learning_outcomes\",\"outcome_index\":1,\"quote\":\"List physicochemical properties of drugs, anatomical structures and molecular machinery that influence drug access to and efflux from the CNS.\",\"source_url\":\"https://guide.wisc.edu/courses/phm_sci/\"}],\"text\":\"Identifying physicochemical properties influencing CNS drug access and efflux\"}],\"summary\":{\"evidence\":[{\"course_id\":\"PHMSCI 770\",\"field\":\"title\",\"quote\":\"CNS DRUG DESIGNS, ACTIONS, AND APPLICATIONS I\",\"source_url\":\"https://guide.wisc.edu/courses/phm_sci/\"},{\"course_id\":\"PHMSCI 770\",\"field\":\"description\",\"quote\":\"Explores how chemical properties influence molecular targets in the central nervous system (CNS), how altered signaling drives physiological changes, and how cholinergic and glutamatergic pharmaceuticals improve patient outcomes.\",\"source_url\":\"https://guide.wisc.edu/courses/phm_sci/\"}],\"text\":\"Explores how chemical properties influence CNS molecular targets and how cholinergic and glutamatergic pharmaceuticals improve patient outcomes through altered signaling.\"},\"topics\":[{\"evidence\":[{\"course_id\":\"PHMSCI 770\",\"field\":\"official_learning_outcomes\",\"outcome_index\":2,\"quote\":\"Describe the major neurotransmitters of the central nervous system, including their physiologic role, distribution, synthesis, storage, and release.\",\"source_url\":\"https://guide.wisc.edu/courses/phm_sci/\"}],\"text\":\"Major CNS neurotransmitters: role, distribution, synthesis, storage, and release\"},{\"evidence\":[{\"course_id\":\"PHMSCI 770\",\"field\":\"official_learning_outcomes\",\"outcome_index\":3,\"quote\":\"Recall the principal mechanisms by which receptors affect cellular signaling in the Central Nervous System.\",\"source_url\":\"https://guide.wisc.edu/courses/phm_sci/\"}],\"text\":\"Receptor mechanisms affecting cellular signaling in the CNS\"},{\"evidence\":[{\"course_id\":\"PHMSCI 770\",\"field\":\"official_learning_outcomes\",\"outcome_index\":5,\"quote\":\"Describe common / serious adverse effects of cholinergic and glutamatergic pharmaceuticals and methods for preventing or minimizing their occurrence.\",\"source_url\":\"https://guide.wisc.edu/courses/phm_sci/\"}],\"text\":\"Adverse effects of cholinergic and glutamatergic pharmaceuticals and prevention methods\"},{\"evidence\":[{\"course_id\":\"PHMSCI 770\",\"field\":\"official_learning_outcomes\",\"outcome_index\":0,\"quote\":\"Identify CNS active drug classes and origins of cholinergic and glutamatergic drugs based in part on structural aspects of the molecule.\",\"source_url\":\"https://guide.wisc.edu/courses/phm_sci/\"}],\"text\":\"Structural aspects of cholinergic and glutamatergic drugs and CNS active classes\"}]}","candidate_json":null,"error":null,"model":"Qwen/Qwen3.8-27B","model_revision":"1d4bf0f2ff6012fd82039f2fa52739d0dd7c60c0","selected_for_release":false},{"run_id":"20261014T203208-0851c9a1","observed_at":"2026-10-14 17:50:09.728220+00:00","course_uid":"course_3fccebda183122da4a95adb6","course_id":"PHMSCI 770","catalog_version_id":"0cf9d39503f57a361961824645422b3c707ec8e9ae93ca29aa86cd5d41fcc6bd","record_version_id":"3ddf615594aad5b59aa7956995d2511a271a5afcf813978a8b45fc10086d6f3e","job_id":"enrich-6556a505c10f448d98d02466","output_id":"141adddc0e7045dcc2de75d2697107d842d2156cdcd111388012bfe7eee3b41c","section":"student_experience","status":"insufficient_evidence","value_json":"{\"status\":\"insufficient_evidence\",\"themes\":[]}","candidate_json":null,"error":null,"model":"Qwen/Qwen3.8-27B","model_revision":"1d4bf0f2ff6012fd82039f2fa52739d0dd7c60c0","selected_for_release":false},{"run_id":"20260907T155543-ce3781c4","observed_at":"2026-09-07 15:55:43.033547+00:00","course_uid":"course_3fccebda183122da4a95adb6","course_id":"PHMSCI 770","catalog_version_id":"f6477f279dae5c75278010d122a5ffa7397ded5a5db8c1ec0a762d14306f6467","record_version_id":"3fe82b78da6106da037370637cb182711f649ef50c59fe8ba86c8554e0a230bf","job_id":"enrich-8b774950c2b6adfdc46d1b82","output_id":"41c10563bfd85720fba04cad3d0937cc8ff27bc1ad8ba38ac070a0d75ede1639","section":"requirements","status":"valid","value_json":"{\"nodes\":[{\"children\":[],\"condition\":\"Declared in MS Pharmaceutical Sciences\",\"course\":null,\"evidence\":\"Declared in MS Pharmaceutical Sciences\",\"id\":\"n0\",\"kind\":\"condition\"}],\"notes\":[],\"root\":\"n0\",\"status\":\"parsed\"}","candidate_json":null,"error":null,"model":"nvidia/Qwen3.6-35B-A3B-NVFP4","model_revision":"1355db6a052410cfd62085d94b58866fd0f2c3c5","selected_for_release":false},{"run_id":"20260907T155543-ce3781c4","observed_at":"2026-09-07 15:55:43.033547+00:00","course_uid":"course_3fccebda183122da4a95adb6","course_id":"PHMSCI 770","catalog_version_id":"f6477f279dae5c75278010d122a5ffa7397ded5a5db8c1ec0a762d14306f6467","record_version_id":"3fe82b78da6106da037370637cb182711f649ef50c59fe8ba86c8554e0a230bf","job_id":"enrich-8b774950c2b6adfdc46d1b82","output_id":"41c10563bfd85720fba04cad3d0937cc8ff27bc1ad8ba38ac070a0d75ede1639","section":"search_profile","status":"valid","value_json":"{\"assumed_background\":[{\"evidence\":[{\"course_id\":\"PHMSCI 770\",\"field\":\"description\",\"quote\":\"Explores how chemical properties influence molecular targets in the central nervous system (CNS), how altered signaling drives physiological changes, and how cholinergic and glutamatergic pharmaceuticals improve patient outcomes.\"}],\"text\":\"Foundational knowledge in chemistry, molecular biology, and pharmacology related to the central nervous system.\"}],\"search_phrases\":[\"CNS drug design\",\"molecular targets central nervous system\",\"cholinergic glutamatergic pharmaceuticals\",\"primary literature analysis skills\",\"pharmaceutical sciences graduate course\"],\"skills_taught\":[{\"evidence\":[{\"course_id\":\"PHMSCI 770\",\"field\":\"description\",\"quote\":\"Develops skills in primary literature analysis to enable conceptual integration of information across chemical, molecular, cellular, systems, and societal levels.\"}],\"text\":\"Primary literature analysis and conceptual integration across multiple biological and chemical levels.\"}],\"summary\":{\"evidence\":[{\"course_id\":\"PHMSCI 770\",\"field\":\"title\",\"quote\":\"CNS DRUG DESIGNS, ACTIONS, AND APPLICATIONS I\"},{\"course_id\":\"PHMSCI 770\",\"field\":\"description\",\"quote\":\"Explores how chemical properties influence molecular targets in the central nervous system (CNS)\"}],\"text\":\"PHMSCI 770 explores chemical influences on CNS molecular targets and develops primary literature analysis skills.\"},\"topics\":[{\"evidence\":[{\"course_id\":\"PHMSCI 770\",\"field\":\"description\",\"quote\":\"chemical properties influence molecular targets in the central nervous system (CNS)\"}],\"text\":\"Chemical properties and molecular targets in the CNS\"},{\"evidence\":[{\"course_id\":\"PHMSCI 770\",\"field\":\"description\",\"quote\":\"altered signaling drives physiological changes\"}],\"text\":\"Altered signaling and physiological changes\"},{\"evidence\":[{\"course_id\":\"PHMSCI 770\",\"field\":\"description\",\"quote\":\"cholinergic and glutamatergic pharmaceuticals improve patient outcomes\"}],\"text\":\"Cholinergic and glutamatergic pharmaceuticals\"},{\"evidence\":[{\"course_id\":\"PHMSCI 770\",\"field\":\"description\",\"quote\":\"conceptual integration of information across chemical, molecular, cellular, systems, and societal levels\"}],\"text\":\"Conceptual integration across chemical, molecular, cellular, systems, and societal levels\"}]}","candidate_json":null,"error":null,"model":"nvidia/Qwen3.6-35B-A3B-NVFP4","model_revision":"1355db6a052410cfd62085d94b58866fd0f2c3c5","selected_for_release":false},{"run_id":"20260907T155543-ce3781c4","observed_at":"2026-09-07 15:55:43.033547+00:00","course_uid":"course_3fccebda183122da4a95adb6","course_id":"PHMSCI 770","catalog_version_id":"f6477f279dae5c75278010d122a5ffa7397ded5a5db8c1ec0a762d14306f6467","record_version_id":"3fe82b78da6106da037370637cb182711f649ef50c59fe8ba86c8554e0a230bf","job_id":"enrich-8b774950c2b6adfdc46d1b82","output_id":"41c10563bfd85720fba04cad3d0937cc8ff27bc1ad8ba38ac070a0d75ede1639","section":"student_experience","status":"insufficient_evidence","value_json":"{\"status\":\"insufficient_evidence\",\"themes\":[]}","candidate_json":null,"error":null,"model":"nvidia/Qwen3.6-35B-A3B-NVFP4","model_revision":"1355db6a052410cfd62085d94b58866fd0f2c3c5","selected_for_release":false},{"run_id":"20260907T155543-ce3781c4","observed_at":"2026-09-07 15:55:43.033547+00:00","course_uid":"course_3fccebda183122da4a95adb6","course_id":"PHMSCI 770","catalog_version_id":"f6477f279dae5c75278010d122a5ffa7397ded5a5db8c1ec0a762d14306f6467","record_version_id":"3fe82b78da6106da037370637cb182711f649ef50c59fe8ba86c8554e0a230bf","job_id":"enrich-8b774950c2b6adfdc46d1b82","output_id":"41c10563bfd85720fba04cad3d0937cc8ff27bc1ad8ba38ac070a0d75ede1639","section":"student_summary","status":"valid","value_json":"{\"context_hash\":\"9a97bb3d285919998e20fc646656172f816c90fd7c21d57e51300569ac361489\",\"course_id\":\"PHMSCI 770\",\"current_instructors\":[{\"instructor_uid\":\"instructor_4665262be09bc2f212f8530f\",\"message\":\"No course-specific reviews available\",\"name\":\"Charles Lauhon\",\"review_status\":\"no_course_reviews\",\"rmp_instructor_id\":null,\"summary\":[]},{\"instructor_uid\":\"instructor_c542cb2db8a9ed5e1f19d360\",\"message\":\"No course-specific reviews available\",\"name\":\"Cody Wenthur\",\"review_status\":\"no_course_reviews\",\"rmp_instructor_id\":null,\"summary\":[]},{\"instructor_uid\":\"instructor_8b93b1a07597494f4dccd540\",\"message\":\"No course-specific reviews available\",\"name\":\"Zachary Del Mundo\",\"review_status\":\"no_course_reviews\",\"rmp_instructor_id\":null,\"summary\":[]}],\"difficulty_workload\":[],\"errors\":[],\"historical_context\":[],\"message\":\"No course-specific reviews available\",\"offered\":true,\"profile_hash\":\"5cb4dabf887cdbcd8c00d5a1312e10828b95c63f30bc3ea76aea199565390d02\",\"quick_take\":[{\"citations\":[{\"course_id\":\"PHMSCI 770\",\"run_id\":\"20260907T155543-ce3781c4\",\"source_record\":{\"entity_id\":\"ee8e37bd-e595-3df5-a266-87f2b3460a8a\",\"file\":\"tables/observations.parquet\",\"kind\":\"grades\",\"source\":\"madgrades\"},\"table\":\"grades_latest\",\"term_id\":\"1074\",\"type\":\"grade\"}],\"text\":\"Recent recorded grades — Spring 2007: 3.77 GPA, 92.3% A/AB (n=13 letter grades).\"}],\"student_experience\":[],\"task_hash\":\"74fb0997943e888960bbc9e47db8c4fd12e4292d55c20509d8d89db6a9910f68\",\"teaching_history\":[],\"term_id\":\"1272\",\"term_name\":\"2026 Fall\",\"version\":2}","candidate_json":null,"error":null,"model":"nvidia/Qwen3.6-35B-A3B-NVFP4","model_revision":"1355db6a052410cfd62085d94b58866fd0f2c3c5","selected_for_release":false}]